Literature DB >> 29989538

Bavencio® (Avelumab)-A Newly Approved Anti-PD-L1 IgG1 Antibody.

Aditya K Gupta1,2, Sarah G Versteeg2, William Abramovits3,4,5, Kimberly D Vincent6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29989538

Source DB:  PubMed          Journal:  Skinmed        ISSN: 1540-9740


× No keyword cloud information.
  1 in total

Review 1.  Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.

Authors:  Mariana Segovia-Mendoza; Susana Romero-Garcia; Cristina Lemini; Heriberto Prado-Garcia
Journal:  J Immunol Res       Date:  2021-01-07       Impact factor: 4.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.